Merck Strengthens Oncology Pipeline Through Strategic Partnership with Hengrui for Next-Generation Selective PARP1 Inhibitor and Antibody-Drug Conjugate
Agreement represents strong strategic fit that leverages the company’s internal DNA damage response expertise and in-house ADC capabilities